MGB Biopharma seeks a partner interested in genuine novelty in the antibiotics field, such as our MGB platform.  We recognise that this is paramount in terms of market need, where resistant strains of bacteria are rendering the successful use of antibiotics with existing mechanisms of action less effective.  As we have several different formulations in development for MGB-BP-3, we are able to consider separate partners where there is a specific fit, or alternatively work with a single partner.  As the technology shows promise for distinct subfamilies of chemistry being applicable to other areas, including Gram-negative bacteria, viral and parasitic diseases, we are interested in exploring research collaborations to bring these programmes to formal development stages.

 

Contact: dfirmin@mgb-biopharma.com